Hussein Al-Fiadh

Mr. Hussein Al-Fiadh

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMarwan Shawki
Marwan Shawki
NWNeshi Minoya Weerasooriya
Neshi Minoya Weerasooriya
ASAnthony Salib
Anthony Salib
HAHussein Al-Fiadh
Hussein Al-Fiadh
CZChantelle Zoumberis
Chantelle Zoumberis
AAAli Al-Fiadh
Ali Al-Fiadh
Background/Objectives: The Rapid Access Chest Pain Assessment Clinic (RACPAC) streamlines the evaluation of low-to-intermediate risk chest pain and helps avoid unnecessary hospitalisation. Biomarkers {low-density lipoprotein cholesterol (LDL-c) and high-sensitivity C-reactive protein (hsCRP)} are established cardiovascular risk markers. Yet, their diagnostic value for stable coronary artery disease (CAD) in RACPAC remains uncertain. Therefore, we aimed to determine the utility of biomarkers in predicting the presence of CAD in the RACPAC setting. Methods: A retrospective cohort study of consecutive adults attending RACPAC between 2012 and 2021. Multivariable logistic regression and receiver operating characteristic analyses, including prespecified subgroup and sensitivity analyses, were used to evaluate the predictive value of hsCRP and LDL-c for the presence of CAD detected on CT Coronary Angiogram (CTCA) or Treadmill Stress Echocardiography (TSE) as the primary outcome. Results: 3569 patients were included in this study, the mean age was 55.4 ± 11.3 years, and 48.8% were female; 37.4% had hypertension, while 39.5% had dyslipidemia. The mean LDL-c was 3.1 ± 0.9 mmol/L, and the median hsCRP was 1.9 mg/L (IQR 0.9 to 3.8). The regression analysis for the primary outcome showed that neither hsCRP nor LDL-c predicted CAD on CTCA (hsCRP OR 1.00, 95% CI 0.99 to 1.02, p = 0.70; LDL-c OR 1.16, 95% CI 0.97 to 1.39, p = 0.11). On TSE, hsCRP was not associated with CAD, while LDL-c showed an inverse association with CAD (hsCRP OR 0.98, 95% CI 0.83 to 1.00, p = 0.78; LDL-c OR 0.44, 95% CI 0.21 to 0.87, p = 0.02). ROC analysis showed AUC 0.553 for log hsCRP (95% CI 0.501 to 0.606) and 0.508 for LDL-c (95% CI 0.450 to 0.566), with p = 0.2756. Conclusions: In a large real-world RACPAC cohort, neither elevated hsCRP nor LDL-c predicted the presence of coronary artery disease in the rapid access chest pain clinic (RACPAC) cohort. In contrast, CT coronary angiography (CTCA) demonstrated superior diagnostic accuracy compared with treadmill stress echocardiography (TSE) in this setting.

11 December 2025 in Scientific Reports
Verified
Journal Article
Open access
HAHussein Al-Fiadh
Hussein Al-Fiadh
RARobert Azzopardi
Robert Azzopardi
MSMarwan Shawki
Marwan Shawki
ZLZhao Feng Liu
Zhao Feng Liu
YLYao-Chen Lin
Yao-Chen Lin
AAAli Al-Fiadh
Ali Al-Fiadh
Rapid Access Chest Pain Assessment Clinic (RACPAC) offers an outpatient evaluation for patients with troponin-negative, low-to-intermediate risk chest pain. This 10-year study assessed its role in the early identification of patients at cardiovascular risk and compared the modes of coronary investigation performances. A single-centre, observational, retrospective cohort study from July 2012 to July 2022 assessed patients who underwent diagnostic tests: CT coronary angiography (CTCA), treadmill stress echocardiogram (TSE), myocardial perfusion scan (MPS), or invasive coronary angiogram (ICA). True positive cases were defined by obstructive disease on subsequent ICA. Baseline characteristics, investigation choice, results, conversion rates to ICA, and identification of new modifiable risk factors to potentially reduce future cardiovascular events were analysed. A total of 3976 patients with low-to-intermediate risk chest pain, mean age (55.2 ± 11.6) years, 51% male, with prevalent risk factors such as positive family history (49%) and dyslipidaemia (42%). Initial investigations: TSE (49.2%), CTCA (43.7%), MPS (4.6%), and ICA (2.5%). CTCA showed superior performance compared to TSE in positive predictive value (97% vs. 82%), negative predictive value (66% vs. 27%) for those proceeding to ICA despite initial negative/inconclusive results, and attendance rates (97% vs. 92%). Incidental findings occurred in 4% of cases, predominantly with CTCA. New modifiable CVD risk factors were identified in 33% of patients, and 17% had CAD with pre-existing CVD risk factors needing stricter control. Our study highlights the effectiveness of CTCA as a primary investigation for troponin-negative, low-to-intermediate risk chest pain patients, with high predictive values, incidental findings and attendance rates. It also emphasises RACPAC's potential role in identifying patients at cardiovascular disease risk and perhaps reducing future cardiovascular morbidity and mortality.